Ascendis Pharma AS (ASND)
130.43
+6.15
(+4.95%)
USD |
NASDAQ |
Nov 15, 14:20
Ascendis Pharma Free Cash Flow (Quarterly)
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -110.55M |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | -169.89M |
| March 31, 2023 | -159.10M |
| December 31, 2022 | -170.63M |
| September 30, 2022 | -87.56M |
| June 30, 2022 | -128.80M |
| March 31, 2022 | -151.04M |
| December 31, 2021 | -152.87M |
| September 30, 2021 | -122.95M |
| June 30, 2021 | -143.17M |
| March 31, 2021 | -103.84M |
| December 31, 2020 | -103.72M |
| September 30, 2020 | -82.96M |
| June 30, 2020 | -67.58M |
| March 31, 2020 | -80.48M |
| December 31, 2019 | -57.37M |
| September 30, 2019 | -67.25M |
| June 30, 2019 | -6.177M |
| March 31, 2019 | -71.94M |
| Date | Value |
|---|---|
| December 31, 2018 | -45.14M |
| September 30, 2018 | -53.49M |
| June 30, 2018 | -23.14M |
| March 31, 2018 | -45.26M |
| December 31, 2017 | -24.53M |
| September 30, 2017 | -33.89M |
| June 30, 2017 | -27.30M |
| March 31, 2017 | -23.04M |
| December 31, 2016 | -18.14M |
| September 30, 2016 | -17.49M |
| June 30, 2016 | -15.15M |
| March 31, 2016 | -16.57M |
| December 31, 2015 | -11.43M |
| September 30, 2015 | -14.04M |
| June 30, 2015 | -15.77M |
| March 31, 2015 | -8.148M |
| December 31, 2014 | -10.28M |
| September 30, 2014 | -4.210M |
| June 30, 2014 | -6.884M |
| March 31, 2014 | -3.639M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-170.63M
Minimum
Dec 2022
-57.37M
Maximum
Dec 2019
-118.28M
Average
-116.75M
Median
Free Cash Flow (Quarterly) Benchmarks
| Novo Nordisk AS | 4.748B |
| Evaxion Biotech AS | -- |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -1.569M |
| Genfit SA | -- |